Welcome to our dedicated page for Elevation Oncology news (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncology stock.
Elevation Oncology, Inc. (Nasdaq: ELEV) is committed to transforming cancer treatment by developing targeted therapeutics tailored to the unique genomic alterations of each patient's tumor. Founded on the belief that every cancer patient deserves to understand the drivers of their disease, Elevation Oncology focuses on making genomic tests actionable by developing drugs to address specific alterations.
The company's prominent clinical candidate, seribantumab, targets tumors driven by NRG1 fusions and is currently undergoing Phase 2 clinical trials in the CRESTONE study. Another pioneering project, EO-3021, is a promising antibody-drug conjugate (ADC) focusing on Claudin 18.2-expressing cancers. EO-3021 is designed to selectively deliver a payload to cancer cells, minimizing collateral damage to healthy cells. The U.S. FDA has cleared an Investigational New Drug application for EO-3021, and the Phase 1 clinical trial has already commenced in the United States and Japan.
In addition to its robust pipeline, Elevation Oncology has received strategic backing from prominent investors such as Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners. This financial support underscores the confidence in the company's innovative approach and potential for significant impact on cancer treatment.
The latest news includes the announcement from August 3, 2023, revealing financial results for the second quarter of 2023 and highlighting the successful public offering of $46.5 million in net proceeds. Additionally, as of June 30, 2023, Elevation Oncology holds cash reserves of $107.9 million, sufficient to fund operations into the second half of 2025. Furthermore, the first patient has been dosed in the Phase 1 trial for EO-3021, with promising initial data expected by mid-2024.
Elevation Oncology continues to advance its pipeline with a vision to expand treatment options through new and existing partnerships. The company’s focus on precision medicine aims to deliver better outcomes for patients with significant unmet medical needs, reaffirming its commitment to innovation and patient-centered care.
Elevation Oncology, Inc. (Nasdaq: ELEV) announced its participation in two investor conferences this March. The first is the Cowen 42nd Annual Health Care Conference on March 8 at 12:50 p.m. ET, focusing on tumor-agnostic development. The second is the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 12:40 p.m. ET. Both presentations will be available via live webcast on the company's Investor Relations website. Elevation Oncology is dedicated to developing precision medicines for genomically defined cancers.
Elevation Oncology (Nasdaq: ELEV) has shared its 2021 achievements and 2022 expectations. In 2021, key milestones included advancements in seribantumab in the Phase 2 CRESTONE study, a successful IPO raising $106.5 million, and strategic partnerships aimed at identifying new genomic targets. For 2022, the company plans to present initial data from the CRESTONE study and expand its pipeline. As of September 30, 2021, the company anticipates cash reserves of $155.2 million will support operations into Q2 2023.
Elevation Oncology, Inc. (Nasdaq: ELEV) announced participation by CEO Shawn M. Leland in a pre-recorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022. The company focuses on precision medicines for patients with genomically defined cancers, with its lead candidate, seribantumab, targeting NRG1 fusions in solid tumors. The presentation will be available on-demand from 7:00 a.m. ET on the company's investor relations website.
Elevation Oncology, a clinical-stage biopharmaceutical company, announced that Shawn M. Leland, the CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:45 a.m. ET. The presentation will be held virtually, and interested parties can access a live webcast and replay via the company's Investor Relations website.
Elevation Oncology focuses on developing precision medicines for cancers driven by specific genomic alterations, including their lead candidate, seribantumab.
Elevation Oncology, Inc. (Nasdaq: ELEV) will present a corporate overview and engage in one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. An on-demand replay of the presentation will be available starting November 22, 2021, at 10:00 am ET on their Investor Relations website. The company focuses on precision medicines for genomically defined cancers, with lead candidate seribantumab targeting NRG1 fusions in a Phase 2 study. For more details, visit their official site.
Elevation Oncology (Nasdaq: ELEV) reported its third-quarter 2021 financial results, showcasing a net loss of $12.3 million, up from $3.0 million in Q3 2020. Cash and cash equivalents stood at $155.2 million, expected to sustain operations into Q2 2023. The CRESTONE Study for seribantumab has commenced enrollment across the US, Canada, and Australia. Notable clinical data presented indicated a 90% reduction in cancer biomarker CA19-9 in a case study of a patient with NRG1 fusion. The company anticipates completing patient enrollment in mid-2022 and presenting initial clinical results.
Elevation Oncology announced the promotion of Valerie M. Jansen, M.D., Ph.D., to the position of Chief Medical Officer, effective immediately. Jansen, previously the Vice President of Clinical Development, has significantly contributed to the company's vision and clinical programs, including the Phase 2 CRESTONE study targeting NRG1 fusions with the therapeutic seribantumab. The company aims to develop precision medicines for patients with genomically defined cancers, emphasizing the importance of genomic testing to improve treatment outcomes.
Elevation Oncology (Nasdaq: ELEV) announced a case series presentation at the AGITG 2021 Annual Scientific Meeting, highlighting its MoST study. This presentation was recognized as one of the 'Best of the Best.' A patient with treatment-refractory metastatic pancreatic cancer demonstrated lasting response to seribantumab, showing a 90% reduction in the cancer biomarker CA19-9 and a maximum tumor reduction exceeding 50% after over 9 months of treatment. The CRESTONE study, which explores seribantumab's efficacy in NRG1 fusion-positive tumors, is currently enrolling patients.
Elevation Oncology (Nasdaq: ELEV) announced that its CEO, Shawn M. Leland, will virtually present at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on demand from September 13, 2021, at 7:00 a.m. ET. Elevation Oncology focuses on developing precision medicines for genomically defined cancers and aims to provide individualized treatment plans.
The company's lead candidate, seribantumab, targets tumor growth driven by NRG1 fusions and is currently in Phase 2 testing.
Elevation Oncology (Nasdaq: ELEV) reported its Q2 2021 financial results on August 12, 2021, marking a pivotal period following a successful IPO that raised $106.5 million. The company’s cash reserves of $158 million are expected to fund operations into Q2 2023. R&D expenses increased to $3.9 million primarily for the CRESTONE study. The company is on track to enroll its first 20 patients in the study by early 2022 and is expanding its precision oncology pipeline through collaborations with Caris Life Sciences and other diagnostic partners.
FAQ
What is the current stock price of Elevation Oncology (ELEV)?
What is the market cap of Elevation Oncology (ELEV)?
What is Elevation Oncology's main focus?
What is seribantumab?
What is EO-3021?
Who are Elevation Oncology's key investors?
What recent financial achievements has Elevation Oncology announced?
Where is EO-3021 being tested?
What is the purpose of Elevation Oncology's clinical trials?
How does Elevation Oncology approach drug development?
What are Elevation Oncology’s financial expectations?
What was announced during the ASCO 2023 meeting?
